Open Label Safety Investigation of Solutio™ Tumescent Catheter

A Prospective, Open Label Investigation of Safety of the Solutio™ Tumescent Catheter for Endothermal Ablation of Varicose Veins

The goal of this clinical investigation is to evaluate safety of the Solutio™ catheter when administering tumescent anesthesia before treatment with endothermal ablation in adults above the age of 18, who suffer from unilateral insufficiency of the great saphenous vein (GSV).

Main question(s) to answer is:

Safety evaluated through reported Adverse Device Effects (ADEs) and Serious Adverse Device Effects (SADEs).

Incidence of Adverse Events (AE), Adverse Device Effects (ADE), Serious Adverse Events (SAE), Serious Adverse Device Effects (SADE), and device deficiency (DD) throughout the investigation.

All investigation participants will:

• Undergo screening, including medical history, physical examination, and vein mapping with Doppler ultrasound.
• Have their Great Saphenous Vein (GSV) treated using Seldinger technique under ultrasound guidance.
• Receive tumescent anesthesia injected from inside the vein into the perivascular tissue at selected sites along the vein, using the investigational Solutio™ catheter under ultrasound guidance.
• Undergo endothermal ablation, Endovenous Laser Ablation (EVLA), or Radiofrequency Ablation (RFA).
• Be followed up for 28 days through scheduled phone calls (Day 1, Day 14 ±2) and clinic visits (Day 7 ±1, Day 28 ±2) to assess adverse events, pain, patient comfort, and undergo physical/clinical examinations and ultrasound examinations of the treated area.

Study Overview

• Status: Not yet recruiting
• Conditions: Venous Insufficiency
• Intervention / Treatment: Device: Administration of local anesthesia

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Ingegerd W Dalfelt, SRN, BSc.; Phone Number: +46708433348; Email: ingegerd.dalfelt@gmail.com
• Study Contact Backup: Name: Cathrin Johansson, BSc; Phone Number: +46708548834; Email: cathrin.johansson@medvasc.se

Study Locations

• Sweden
  • Halmstad, Sweden, 301 85
    • Hallands sjukhus
    • Contact: Karin Ludwigs, MD; Phone Number: +46 (0)35 14 77 53; Email: Karin.Ludwigs@regionhalland.se
  • Malmö, Sweden, 21135
    • Scandinavian Venous Centre
    • Contact: Karin Ludwigs, MD; Phone Number: +46707382447; Email: karin.ludwigs@svcgoteborg.se

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or Female >18 years old.
2. Subject diagnosed with venous insufficiency in the Great Saphenous Vein from the groin to the proximal 1/3 of the lower leg and with a Clinical Etiological Anatomical Pathophysiological (CEAP) classification of 2 or higher.
3. Subject is scheduled for an EVLA or RFA procedure for a unilateral insufficiency of the GSV.
4. Subject accepts to be treated with endothermal ablation as a standalone method.
5. Subject accepts to be treated without any sedation.
6. Subject is willing and able to provide written informed consent.

Exclusion Criteria:

1. Considered as being of high risk due to comorbidity in the opinion of the investigator.
2. Subject with known and confirmed coagulation defects.
3. Subject on anticoagulant treatment.
4. Subject who simultaneously needs to be treated with other supplemental techniques such as e.g., foam sclerotherapy, ligation, and phlebectomy.
5. Subject with GSV insufficiency in the distal 2/3 of the lower leg.
6. Subject, who demands full sedation, or general anesthesia.
7. Subject with known allergy to any of the tumescent and/or anesthetizing agents that will be used (per local standard practice) during the endothermal ablation procedure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Solutio™ catheter used to administrate tumescence during endothermal ablation of varicose veins; Administration of tumescence from inside the vein to the surrounding tissue, via Solutio™ catheter during endothermal ablation of varicose veins.

Device: Administration of local anesthesia; The Solutio™ catheter presents a technique that allows for tumescent anesthesia injections to be administered at selected sites along the vein, from inside the vein to the surrounding tissue. The purpose of the Solutio™ catheter is to prevent the pain associated with multiple injections, through sensitive skin layers along the inner side of the leg, administered prior to ablation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety related to the procedure using the Solutio™ catheter.	Safety evaluated by recording the number and type of adverse device effects (ADEs) and serious adverse device effects (SADEs) related to the procedure using the Solutio™ catheter.	28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient experience of pain	The patient will rate their experience of pain at follow up visits at the clinic and via phone contacts. A Visual Analogue Scale (VAS) measures pain intensity. The scale consists of a 100 mm line, with two end points representing 0 = "no pain" and 100 = "worst pain imaginable". The patient will be asked to make a mark across the line according to the maximum experienced pain to indicate their pain at given timepoints. At phone contacts the patient is asked a standard question to rate their pain with a number from 0 to 10, a Numeric Rating Scale (NRS), where 0 = "no pain" and 10 = "worst pain imaginable"	28 days
Physician feedback	After the end of the procedure, the physician is asked to provide their feedback, assessment about 10 different aspects during the procedure. They will answer with a 4-grade scale (1 is excellent, 2 is good, 3 is fair, 4 is impossible /inadequate). Acceptable score is ≤3 for each question.	1 day
Patient experience of pain	At phone contacts the patient is asked a standardized question to rate their pain with a number from 0 to 10, a Numeric Rating Scale (NRS), where 0 = "no pain" and 10 = "worst pain imaginable".	28 days

Collaborators and Investigators

• Sponsor: MedVasc AB
• Investigators: Study Director: Michael Akesson, MD, MedVasc AB

Study record dates

Study Major Dates

• Study Start (Estimated): September 28, 2026
• Primary Completion (Estimated): December 30, 2026
• Study Completion (Estimated): February 28, 2027

Study Registration Dates

• First Submitted: September 1, 2026
• First Submitted That Met QC Criteria: September 10, 2026
• First Posted (Actual): September 16, 2026

Study Record Updates

• Last Update Posted (Actual): September 16, 2026
• Last Update Submitted That Met QC Criteria: September 10, 2026
• Last Verified: September 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Venous Insufficiency
• Other Study ID Numbers: CSDPR901

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No